0001209191-22-020953.txt : 20220324 0001209191-22-020953.hdr.sgml : 20220324 20220324174038 ACCESSION NUMBER: 0001209191-22-020953 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220323 FILED AS OF DATE: 20220324 DATE AS OF CHANGE: 20220324 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sukhtian Faisal Ghiath CENTRAL INDEX KEY: 0001716033 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 22767670 MAIL ADDRESS: STREET 1: 7TH CIRCLE, ZAHRAN ST. STREET 2: ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909 CITY: AMMAN STATE: M2 ZIP: 11844 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-23 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001716033 Sukhtian Faisal Ghiath C/O OUTLOOK THERAPEUTICS, INC. 485 ROUTE 1 SOUTH, BUILDING F, SUITE 320 ISELIN NJ 08830 1 0 0 0 Stock Option (Right to Buy) 1.92 2022-03-23 4 A 0 21878 0.00 A 2032-03-23 Common Stock 21878 21878 D The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. /s/ Lawrence Kenyon, Attorney-in-Fact 2022-03-24